Drug discovery

#CRISPR #Drug discovery #Precision medicine #Therapeutics

Therapeutics: Changing the way we treat disease – podcast 

The latest free-to-listen DDW podcast episode is titled “Therapeutics: Changing the way we treat disease”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas.  These articles are titled: “Avoiding double strand breaks on… Read More

#News

#Biosciences #Cancer research #Drug development #Drug discovery #Oncology #Precision medicine

Anticancer Bioscience expands to Chinese biotech research park 

Anticancer Bioscience, a company developing synthetic lethal approaches to precision oncology, have relocated to Tianfu International Biotown, in Chengdu, China, to accommodate its growth and expansion, and on the back of its recent financing. Biotown is considered the premier biotech research park in Chengdu, the capital of Sichuan province.  The… Read More

#News

Artificial Intelligence
#AI / data analytics / healthtech / informatics #Biotechnology #Drug discovery #Drug targets

Collaboration to use AI for drug design and retrosyntheis 

The Drug Discovery Unit (DDU) in the School of Life Sciences at The University of Dundee is using Iktos’ generative modelling artificial intelligence (AI) technology in one of its drug discovery programmes.  The collaboration   Iktos will apply its de novo ligand and structure-based generative modelling technologies, its AI-based… Read More

#News

#Drug discovery #Genetic editing #Hit identification #Medicinal chemistry #Podcast

Using biotechnology to maximise drug discovery output – podcast 

The latest free-to-listen DDW podcast episode is titled “Using biotechnology to maximise drug discovery output”. It covers two articles written for Volume 22, Issue 2 – Spring 2021 of the Drug Discovery World Magazine and has been narrated by DDW’s Megan Thomas.  These articles are titled: “The important integration of medicinal chemistry in Hit-to-Lead… Read More

#News

#Drug development #Drug discovery #Healthcare #Library screening #Screening

TropIQ: Digitalising drug discovery for vector-borne diseases 

More than half of the world’s population is at risk from vector-borne diseases that are transmitted by insects such as mosquitoes, flies and ticks. These diseases cause more than one million deaths annually, and it is primarily people in the poorest countries who are the most vulnerable. Sophia Ktori shares… Read More

#Editor's Choice #Exclusive Content #News

#Covid-19 #Drug development #Drug discovery

This week in drug discovery (6-10 December) 

News round-up by DDW’s Megan Thomas for 6-10 December  In the wake of the discovery of the Omicron Covid-19 variant globally, DDW’s Megan Thomas rounds up five news stories which show the strides being made to understand and fight this variant across the drug discovery industry. … Read More

#News

#Collaboration #Drug development #Drug discovery #Genomics #Machine learning

GSK and Oxford University team up to unravel mechanisms of disease 

GlaxoSmithKline (GSK) and the University of Oxford have announced a five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine, which will be based at the University of Oxford and improve the success and speed of research and development of new medicines, building on insights from human… Read More

#News

#Clinical trials #Covid-19 #Drug discovery #Immunology / Virology & Vaccines #Omicron

Preclinical data of drug demonstrates protection against Omicron 

Following the approval of GlaxoSmithKline (GSK) and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), the companies have announced an update, with preclinical data demonstrating that sotrovimab, an investigational monoclonal antibody, retains activity against key mutations of the new Omicron SARS-CoV-2 variant (B.1.1.529), including those found in the binding site of sotrovimab.  … Read More

#Covid-19 #News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Omicron #Therapeutics

Breakthrough: New drug for Omicron and coronavirus strains 

Infex Therapeutics scientists have announced a breakthrough in laboratory trials of a new drug to treat Covid-19 and new variants of the disease, such as the Omicron variant.   Infex’s COV-X programme inhibits a new protease target that is responsible for viral replication across the broad spectrum of SARS-CoV-1, MERS-CoV and SARS-CoV-2. As such,… Read More

#Covid-19 #News #Trending News

#Biotechnology #Covid-19 #Drug discovery #Immunology / Virology & Vaccines

Covid-19 treatment cuts hospitalisation and death by 79% 

The Medicines and Healthcare products Regulatory Agency (MHRA), in the UK, has approved GSK and Vir Biotechnology’s Covid-19 drug Xevudy (sotrovimab), after it was found to be safe and effective at reducing the risk of hospitalisation and death in people with mild to moderate Covid-19 infection who are at an increased risk of developing severe… Read More

#Covid-19 #News #Trending News

#AI / data analytics / healthtech / informatics #Clinical trials #Drug discovery

First-in-Human Study of a novel drug discovered using AI platform 

Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company, has announced that the first healthy volunteer has been dosed in a first-in-human microdose trial of ISM001-055.  What is ISM001-055?  ISM001-055 is a potentially first-in-class small molecule inhibitor of a novel biological target discovered by Pharma.AI, Insilico Medicine’s end-to-end AI-powered… Read More

#News

#Clinical trials #Drug development #Drug discovery #Tumours

FDA approves Avacta’s new cancer therapy drug

The US Food and Drug Administration (FDA) has approved Avacta’s Investigational New Drug (IND) application for AVA6000, which will allow the group to expand its Phase I clinical trial, ALS-6000-101, into clinical trial sites in the United States.  What is AVA6000?  AVA6000 is a novel form of… Read More

#Cancer Research #News

#Autoimmune disease #Biology #Drug development #Drug discovery #Research study #Therapeutics

Human-on-a-Chip approach validated to model rare autoimmune disease

A new peer-reviewed article demonstrated that Hesperos’ Human-on-a-Chip (HoaC) cell-based neuromuscular junction (NMJ) platform system can mimic the disease phenotypes of myasthenia gravis (MG). The manuscript, titled “A Functional Human-on-a-Chip Autoimmune Disease Model of Myasthenia Gravis for Development of Therapeutics,” was published in Frontiers in Cell and Developmental Biology. Read More

#News

#Biopharmaceuticals #Drug development #Drug discovery #Immunology / Virology & Vaccines #In vivo

Agreement to develop vaccines against cancer and infectious diseases 

Nykode Therapeutics (formerly Vaccibody) has entered into a license and collaboration agreement with Regeneron for the discovery, development and commercialisation of potential new vaccines for cancer and infectious diseases.  What is the structure of the agreement?  The agreement includes five programmes, three within cancer and two within infectious diseases. Read More

#News

#CAR-T #DNA #Drug development #Drug discovery #Podcast #Synthetic biology

Podcast: Building on current drug discovery methods

This is the latest episode of the free DDW podcast, “Building on current drug discovery methods”. It covers two narrated article written for Volume 22, Issue 2 – Spring 2021 of DDW and read aloud by Megan Thomas. The articles are called “The new synthesis: How synthetic DNA technology is… Read More

#News #Trending News